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Abstract
Introduction: Risk factor analyses for nosocomial infections (NIs) are complex. First, due to competing events for NI,
the association between risk factors of NI as measured using hazard rates may not coincide with the association using
cumulative probability (risk). Second, patients from the same intensive care unit (ICU) who share the same
environmental exposure are likely to be more similar with regard to risk factors predisposing to a NI than patients from
different ICUs. We aimed to develop an analytical approach to account for both features and to use it to evaluate
associations between patient- and ICU-level characteristics with both rates of NI and competing risks and with the
cumulative probability of infection.
Methods: We considered a multicenter database of 159 intensive care units containing 109,216 admissions (813,739
admission-days) from the Spanish HELICS-ENVIN ICU network. We analyzed the data using two models: an etiologic
model (rate based) and a predictive model (risk based). In both models, random effects (shared frailties) were
introduced to assess heterogeneity. Death and discharge without NI are treated as competing events for NI.
Results: There was a large heterogeneity across ICUs in NI hazard rates, which remained after accounting for
multilevel risk factors, meaning that there are remaining unobserved ICU-specific factors that influence NI occurrence.
Heterogeneity across ICUs in terms of cumulative probability of NI was even more pronounced. Several risk factors
had markedly different associations in the rate-based and risk-based models. For some, the associations differed in
magnitude. For example, high Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were associated
with modest increases in the rate of nosocomial bacteremia, but large increases in the risk. Others differed in sign, for
example respiratory vs cardiovascular diagnostic categories were associated with a reduced rate of nosocomial
bacteremia, but an increased risk.
Conclusions: A combination of competing risks and multilevel models is required to understand direct and indirect
risk factors for NI and distinguish patient-level from ICU-level factors.
Introduction
Nosocomial infections (NIs) are a major threat for hospi-
talized patients, particularly in intensive care units (ICUs),
because they are associated with increased mortality and
morbidity [1,2]. Analysis of data from large multicenter
studies has the potential to improve our understanding
of how patient- and ICU-level characteristics impact NI
outcomes. Such analysis is, however, complicated by two
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factors: unexplained ICU-level variation and the impor-
tance of competing risks.
First, there are endogenous and exogenous modes of
NI acquisition [3]. Harbarth et al. [3] showed that about
20% of NIs are exogenous and therefore potentially pre-
ventable. Potential transmission routes of exogenous NIs
are contact with contaminated environmental surfaces or
cross-transmission via health-care workers or patients.
Thus, patients from the same ICU who share the same
environmental exposure are likely to be more similar
with regard to acquiring a NI than patients from differ-
ent ICUs. In addition to patient-individual characteristics,
ICU-specific factors, such as number of beds and nurses,
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type of ICU and infection control policies, are poten-
tial determinants for the occurrence of NI. To distinguish
patient-level and ICU-specific factors requires multilevel
analysis, but this is rarely used in hospital epidemiology
[4]. The clustered structure of the data (patients within
ICUs) often contains information that can be of value in
understanding associations between risks and NIs [5].
Second, the length of ICU stay is a key determinant of
the risk of NI. However, most patients are discharged from
ICU or die in ICU without NI. Factors that are associ-
ated with a high increased rate of infection are often also
associated with an increased risk of dying in the hospital
as well as with an extended length of stay. These compet-
ing events play an important role in risk interpretation of
NI and make extended survival models necessary [6-9].
Again, rates of NI, discharge and death without NI might
also depend on patient- as well as on ICU-level factors.
Thus, a combination of extended survival and multilevel
models is required to understand how different risk fac-
tors impact NI outcomes. The aim of this paper is to apply
established and innovative statistical methods [10,11] to
investigate heterogeneity in risks and rates across ICUs of
NI and concurrently occurring competing events.
Material andmethods
Spanish ICU data
We used a multicenter database from the Spanish surveil-
lance network HELICS-ENVIN [12], embedded in the
HELICS project (Hospitals in Europe Link for Infection
Control through Surveillance). The reliability and quality
of the surveillance program has recently been investigated
[13]. Data were prospectively collected on an individ-
ual patient level and also aggregate ICU level. For our
purpose, we included ICUs that contributed to the reg-
istry between January 2006 and December 2011 and we
included only patients who stayed at least two days in ICU.
We excluded ICUs that contributed less than 100 patient
admissions to the cohort to reduce artificial heterogene-
ity. To get a robust outcome, we focused on primary or
secondary nosocomial bacteremia (NB). The study pop-
ulation, 159 intensive care units with 109,216 admissions
(813,739 admission-days), is summarized in Table 1. The
data of this official surveillance are encrypted and com-
pletely anonymous. Patients’ consent was not needed.
This Deutsche Forschungsgemeinschaft research project
was approved by the ethics committee of the University
Medical Center Freiburg, Germany.
Shared frailty models for competing risks
Model 1: etiologicmodel (rate-based)
The classic way to analyze competing risks data is to study
event-specific hazard rates, i.e., fitting a proportional
hazard model for each event (NB, death without NB and
discharge without NB) separately. Random effects for each
ICU (i.e. frailties) can be introduced by a shared gamma
frailty model [10,14] (see details in Additional file 1). For
each of the three events (NB, death and discharge), we fit-
tedmodels to assess heterogeneity for NB rates, quantified
by the corresponding variance estimator θ . Large vari-
ances signify a closer similarity between patients within
ICU and greater heterogeneity across ICUs. The follow-
ing quantities were calculated for each of the three events:
the baseline hazard, ICU effects, variance of ICU effects
(θ ) and the hazard ratios for multilevel risk factors at
the patient and ICU levels. In this approach, the hazards,
i.e., the daily risks of the primary outcome (NB) and the
competing events (death or discharge without NB), are
studied. Note that the hazard of NB does not depend on
the competing events.
Model 2: predictivemodel (risk-based)
The cumulative incidence function of NB is defined as the
probability of NB over a period of time and interpreted
as the actual risk of NB occurring in this time period.
This approach is useful for predicting NB. It has previ-
ously been shown that the way in which risk factors are
associated with the NB hazard (instantaneous risk) may
not coincide with the way these factors are associated with
the cumulative incidence of NB (cumulative risk) [15].
To study the risk (cumulative incidence function) of NB,
we used the Fine and Gray model [16] and introduced a
shared frailty structure to investigate heterogeneity in a
similar way as Katsahian et al. [11]. Using this model we
calculated the following quantities: the baseline subdistri-
bution hazard and corresponding cumulative incidence of
NB, ICU effects, variance of ICU effects (θ ) and the sub-
distribution hazard ratios for multilevel risk factors at the
patient and ICU levels. In this approach, the cumulative
risk of the primary outcome (NB) is studied. In contrast
to the event-specific approach, the cumulative risk of NB
depends on the NB hazard as well as on the hazards of the
competing events and it tends towards the overall risk, i.e.,
the incidence proportion of NB.
For both models, we first used a model with frail-
ties for each ICU but without covariates (null model).
Then, we considered a multivariate model by introducing
patient-individual as well as ICU-specific covariates and
estimated the frailties for each ICU. For all analyses we
used the flexible R package frailtyPack [17].
Results
In the following we present the detailed results for pri-
mary and secondary nosocomial bacteremia (NB).
Baseline hazard rates and cumulative incidence function
The overall baseline hazard rates based on the null models
without covariates are shown for each event in Figure 1.
The hazard rate of NB is increasing with the time from
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Table 1 Description of study population
General Frequency
Number of admissions 109,216
Number of admission-days 813,739
Number of ICUs 159
Number of nosocomial bacteremia during ICU stay 5,498 (5.03%)
Number of deaths without NB during ICU stay 12,678 (11.61%)
Number of discharges without NB from ICU 90,142 (82.54%)
Number of administrative censored admissions 898 (0.82%)
Overall risk of nosocomial bacteremia (censored excluded) 5.08%
Overall rate of nosocomial bacteremia 6.75 / 1,000 admission-days
Risk factors Frequency (%) Frequency (%)
(patient level) (ICU level)
ICU / hospital level covariates
Number of beds in ICU:
0 to 10 (reference) 30,389 (27.82) 61 (38.36)
11 to 20 46,524 (42.60) 71 (44.65)
21 to 30 21,668 (19.84) 19 (11.95)
31 to 40 7,673 (7.03) 5 (3.14)
> 40 2,962 (2.71) 3 (1.89)
Number of beds in hospital:
0 to 500 (reference) 52,426 (48.00) 94 (59.12)
501 to 1,000 8,259 (7.56) 10 (6.29)
> 1,000 48,531 (44.44) 55 (34.59)
Type of hospital:
Private 6,541 (5.99) 12 (7.55)
Public 102,675 (94.01) 147 (92.45)
Type of ICU:
Polyvalent (reference) 96,478 (88.34) 138 (86.79)
Medical 3,895 (3.57) 5 (3.14)
Surgery 3,103 (2.84) 3 (1.89)
Coronary 525 (0.48) 2 (1.26)
Traumatology 3,273 (3.00) 6 (3.77)
Post-surgery cardiology 1,834 (1.68) 4 (2.52)
Burn 108 (0.10) 1 (0.63)
University+teaching hospital (reference) 67,917 (62.19) 86 (54.09)
Teaching hospital (no university) 30,089 (27.55) 52 (32.70)
Hospital without teaching/university 11,210 (10.26) 21 (13.21)
Calendar year of admission
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Table 1 Description of study population (Continued)
Patient level covariates
APACHE II score:
0 to 10 (reference) 40,353 (36.95)
11 to 20 44,654 (40.89)
21 to 30 19,191 (17.57)
> 30 5,018 (4.59)
Age (years):
0 to 40 54,477 (49.88)
41 to 60 12,931 (11.84)
61 to 80 (reference) 29,371 (26.89)
> 80 12,437 (11.39)
Days in hospital before ICU admission:
0 to 3 (reference) 87,208 (79.85)
4 to 6 5,864 (5.37)
7 to 10 4,962 (4.54)
> 10 11,182 (10.24)
Type of diagnosis:
Cardiovascular (reference) 54,374 (49.79)
Respiratory 15,243 (13.96)
Gastrointestinal 14,626 (13.39)
Central nervous system 17,567 (16.08)
Other diagnoses 7,406 (6.78)
Antibiotic treatment 48 h before and/or after ICU admission 23,178 (21.22)
Gender (male) 71,223 (65.21)
Origin: community (reference) 54,996 (50.36)
Origin: hospital/ICU 54,220 (49.64)
Trauma 8,927 (8.17)

























































































Figure 1 Estimated baseline hazard functions for the three outcomes. Data are from the null model without covariates. Associated 95%
confidence intervals are shown as broken lines.
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Figure 2 Estimated subdistribution hazard function (left) and cumulative incidence function (right). Data are from the shared frailty model
for the subdistribution hazard of NB without covariates. The subdistribution hazard is shown as the black curves and associated 95% confidence
intervals as broken lines.
admission and has a peak at day 15; for instance, the daily
risk of acquiring a NB at day 10 (day 30) for a patient is
about 1% (1.5%) given that he or she has stayed at ICU
without a NB for at least 9 days (29 days). The death haz-
ard rate without NB is about 2% for the first 40 days from
admission. Obviously, the discharge hazard rate without
NB is the strongest hazard with its peak (about 25%) about
5 to 6 days after admission and a strong decrease after-
wards; meaning the likelihood of discharge without NB
decreases for each survived day in ICU. The subdistribu-
tion hazard function and cumulative incidence function
of NB are displayed in Figure 2; the cumulative incidence
function tends towards the overall risk of 5.08%.
Heterogeneity across ICUs
The corresponding ICU effects (random effects or frail-
ties) of the null models are shown in Figure 3; for instance,
an ICU effect of 2 means that the baseline hazard of this
ICU is twice as large as the hazard averaged over all ICUs.
The observed heterogeneity across ICUs in the rates of
NB is remarkably large (θ = 0.26 with standard error
(SE)= 0.038), in contrast to the heterogeneity in rates of
death without NB (θ =0.14 with SE= 0.019) and discharge
without NB (θ =0.15 with SE= 0.017). The heterogeneity
in risks of NB is even larger than in the rates (estimated by
θ = 0.64 with SE= 0.076); see Figure 4. Large heterogene-
ity means that event times are strongly correlated within
ICUs. One might conclude that observed and unob-
served ICU-specific factors play a more substantial role
in the NB hazard rates compared to the competing event
rates.
Including covariates in the models led to only a small
reduction in ICU-level heterogeneities for all three of the
competing outcomes, with θ falling to 0.19 for NB, still
larger than the heterogeneities in rates of the competing
events (Table 2). Separate models (only ICU-level factors
and only patient-level factors) showed that ICU-level fac-
tors reduced heterogeneity more than the patient-level
Figure 3 Estimated frailties (random effects) for each ICU for the three outcomes. Data are from the null model without covariates. The ICUs
are ordered on the X-axis according to the contributing number of patients; the circles are proportional to the magnitude of contribution of the ICU,
e.g., an ICU with sqrt(Npatients)= 60 contributed 602 = 3600 admissions to the cohort. The Y-axis has a log scale. NB, nosocomial bacteremia.





















Figure 4 Estimated frailties (random effects) for each ICU. Data are from the shared frailty model for the subdistribution hazard of NB without
covariates. The ICUs are ordered on the X-axis according to the contributing number of patients; the circles are proportional to the magnitude of
contribution of the ICU, e.g., an ICU with sqrt(Npatients)= 60 contributed 602 = 3600 admissions to the cohort. The Y-axis has a log scale.
factors (Table 2). It follows that the impact of unobserved
ICU-specific factors is large. The heterogeneity reduction
was stronger in the NB risk than the NB rate model. There
are patient-level factors, such as the APACHE II score,
type of diagnosis and trauma (Table 2), that have a strong
effect in reducing the discharge without NB hazard (the
strongest competing risk hazard), i.e., patients with high
APACHE II scores or trauma stay longer in ICU. There are
also ICU-level factors that are more pronounced: num-
ber of beds in ICU and teaching hospital. Thus, there is
an indirect effect on the risk for NB leading to increased
subdistribution hazard ratios. And strong effects lead to a
reduction in heterogeneity.
Multilevel risk factors: patient level
Results from the risk factor analysis on the patient as
well as ICU level are shown in Table 2. The hazard ratios
for NB from the event-specific analysis (model 1) reflect
direct effects on the occurrence of NB; this event-specific
approach also shows how these factors are associated
with the competing events, i.e., those which have poten-
tially indirect effects on NB. The subdistribution analysis
(model 2) is a summary analysis and studies the effects
on the risk of NB (as a cumulative incidence function).
Factors, i.e., an exposure, with a hazard ratio lower than
1 for the competing events increase the risk of NB since
exposed patients stay longer in the ICU leading to more
NBs in the exposed group. For instance, traumatic patients
are associated with an increased daily risk of NB (hazard
rate= 1.13) and also with a decreased daily risk of being
discharged or dying without NB (both hazard rates lower
than 1). In other words: traumatic patients acquire NB
more frequently per day and in addition, as they stay
longer at ICU, their extended time at ICU is itself a risk
factor for NB, which causes them to acquire more NBs
eventually. This indirectly adds to the cumulative risk of
NB (subdistribution hazard rate= 1.81).
In a similar way, factors with a hazard ratio greater
than 1 for the competing events decrease the risk of NB.
For example, patients older than 80 years acquire fewer
NBs per day than patients aged 61 to 80 years (hazard
rate= 0.77) but they also die (and are discharged)
more frequently per day at ICU (both hazard rates
are greater than 1). This indirect effect additionally
reduces the cumulative risk of NB (subdistribution hazard
rate= 0.51). Often, the hazard ratios for discharge and
death without NB are diametrically opposed; then, the
discharge hazard has usually a stronger indirect effect
because of its larger magnitude compared with the death
hazard (Figure 1). For instance, the APACHE II score is
highly associated with an increased rate of NB but also
highly associated with an increased death (without NB)
rate and a decreased discharge (without NB) rate (i.e.,
with a longer ICU stay). The indirect effect due to an
extended length of ICU stay makes patients with higher
APACHE II score acquire an NB more frequently, which
is quantified by the subdistribution hazard ratios. It is













Table 2 Results frommultivariate analysis
Risk factors Event-specific analysis Subdistribution analysis
Nosocomial bacteremia (NB) Death without NB in ICU Discharge without NB Nosocomial bacteremia
HR (95% CI) HR (95% CI) HR (95% CI) Subdistribution HR (95% CI)
ICU / hospital-level covariates
Number of beds in ICU:
11–20 vs 0–10 1.18 (0.96–1.46) 1.01 (0.87–1.17) 1.43 (1.23–1.67) 1.34 (0.99–1.81)
21–30 vs 0–10 1.31 (0.97–1.77) 0.86 (0.69–1.08) 1.15 (0.89–1.47) 2.17 (1.42–3.30)
31–40 vs 0–10 1.56 (0.98–2.50) 0.81 (0.57–1.14) 1.83 (1.22–2.74) 1.85 (0.95–3.62)
> 40 vs 0–10 1.09 (0.55–2.18) 1.00 (0.60–1.65) 1.37 (0.76–2.48) 1.37 (0.50–3.72)
Number of beds in hospital:
> 1000 vs 0–500 1.30 (0.85–1.99) 0.94 (0.70–1.27) 1.30 (0.90–1.87) 1.32 (0.71–2.47)
501–1000 vs 0–500 1.11 (0.91–1.36) 1.04 (0.90–1.21) 1.13 (0.95–1.34) 1.16 (0.87–1.53)
Teaching hospital (only) vs university+teaching 1.00 (0.82–1.22) 1.03 (0.89–1.20) 1.87 (1.61–2.18) 0.94 (0.71–1.26)
No teaching hospital vs university+teaching 0.71 (0.51–0.97) 1.08 (0.86–1.34) 2.42 (1.92–3.03) 0.59 (0.38–0.91)
Type of hospital (private vs public) 0.98 (0.70–1.39) 0.82 (0.64–1.05) 0.80 (0.61–1.05) 1.18 (0.76–1.85)
Type of ICU:
Medical vs polyvalent 0.71 (0.44–1.14) 1.07 (0.78–1.47) 1.44 (0.99–2.10) 0.57 (0.30–1.08)
Surgery vs polyvalent 1.07 (0.62–1.85) 0.60 (0.40–0.91) 1.20 (0.73–1.96) 1.13 (0.51–2.50)
Coronary vs polyvalent 0.71 (0.28–1.82) 1.27 (0.64–2.51) 0.83 (0.44–1.57) 0.73 (0.24–2.28)
Traumatology vs polyvalent 1.20 (0.79–1.82) 1.03 (0.76–1.40) 1.28 (0.90–1.81) 1.15 (0.64–2.05)
Post-surgery cardiology vs polyvalent 1.47 (0.85–2.54) 0.71 (0.46–1.08) 1.95 (1.27–3.01) 1.39 (0.63–3.05)
Burn vs polyvalent 0.48 (0.16–1.42) 0.70 (0.31–1.62) 0.70 (0.31–1.59) 1.20 (0.30–4.79)
Calendar year of admission
2007 vs 2006 1.02 (0.92–1.13) 1.01 (0.94–1.08) 0.95 (0.92–0.97) 1.02 (0.93–1.13)
2008 vs 2006 0.98 (0.89–1.08) 1.09 (1.02–1.16) 0.93 (0.91–0.95) 1.03 (0.93–1.14)
2009 vs 2006 1.09 (0.99–1.19) 1.02 (0.96–1.09) 0.86 (0.83–0.88) 1.19 (1.09–1.31)













Table 2 Results frommultivariate analysis (Continued)
Patient level covariates
APACHE II score:
11–20 vs 0–10 1.30 (1.20–1.42) 1.99 (1.85–2.14) 0.53 (0.52–0.54) 2.81 (2.59–3.06)
21–30 vs 0–10 1.38 (1.26–1.50) 4.11 (3.83–4.41) 0.28 (0.27–0.28) 4.54 (4.15–4.96)
> 31 vs 0–10 1.54 (1.37–1.73) 6.65 (6.15–7.19) 0.17 (0.17–0.18) 5.78 (5.14–6.49)
Age (years):
0–40 vs 61–80 1.08 (0.99–1.18) 0.59 (0.55–0.64) 1.05 (1.03–1.07) 1.12 (1.02–1.22)
40–60 vs 61–80 1.09 (1.02–1.16) 0.79 (0.76–0.83) 0.98 (0.97–1.00) 1.18 (1.11–1.26)
> 80 vs 61–80 0.77 (0.68–0.86) 1.65 (1.57–1.73) 1.18 (1.15–1.21) 0.51 (0.45–0.57)
Days in hospital before ICU admission:
4–6 vs 0–3 1.12 (1.00–1.25) 1.09 (1.01–1.17) 0.86 (0.83–0.89) 1.27 (1.13–1.42)
6–10 vs 0–3 1.14 (1.01–1.28) 1.18 (1.10–1.27) 0.85 (0.82–0.87) 1.33 (1.18–1.49)
> 10 vs 0–3 1.17 (1.08–1.27) 1.22 (1.16–1.29) 0.78 (0.76–0.80) 1.43 (1.32–1.55)
Type of diagnosis:
Respiratory vs cardiovascular 0.86 (0.80–0.94) 0.93 (0.88–0.98) 0.63 (0.62–0.65) 1.43 (1.32–1.55)
Gastrointestinal vs cardiovascular 1.18 (1.09–1.29) 0.96 (0.91–1.02) 0.78 (0.76–0.79) 1.65 (1.51–1.80)
Central nervous system vs cardiovascular 0.91 (0.84–0.99) 1.41 (1.34–1.49) 0.65 (0.64–0.66) 1.38 (1.28–1.50)
Other diagnoses vs cardiovascular 1.20 (1.08–1.32) 0.78 (0.71–0.85) 0.76 (0.74–0.78) 1.96 (1.78–2.16)
Antibiotic treatment 48 h before and/or after ICU admission 0.83 (0.77–0.88) 1.08 (1.04–1.13) 0.70 (0.69–0.71) 1.01 (0.95–1.09)
Gender 1.08 (1.01–1.14) 1.01 (0.97–1.05) 0.99 (0.98–1.01) 1.12 (1.06–1.18)
Origin (hospital/ICU vs community) 1.05 (0.98–1.12) 0.98 (0.94–1.02) 1.00 (0.99–1.02) 1.09 (1.02–1.17)
Trauma 1.13 (1.04–1.24) 0.67 (0.62–0.72) 0.64 (0.62–0.66) 1.81 (1.66–1.98)
Variance of heterogeneity (without covariates) 0.26 (SE 0.038) 0.14 (SE 0.019) 0.15 (SE 0.017) 0.64 (SE 0.076)
Variance of heterogeneity (with ICU-level covariates only) 0.20 (SE 0.030) 0.12 (SE 0.015) 0.09 (SE 0.011) 0.47 (SE 0.061)
Variance of heterogeneity (with patient-level covariates only) 0.25 (SE 0.037) 0.12 (SE 0.016) 0.17 (SE 0.025) 0.56 (SE 0.069)
Variance of heterogeneity (with all covariates) 0.19 (SE 0.030) 0.11 (SE 0.015) 0.17 (SE 0.024) 0.40 (SE 0.052)
CI, confidence interval; HR, hazard rate; NB, nosocomial bacteremia; SE, standard error.
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1 but for the subdistribution hazard ratio to be larger
than 1 (such as respiratory vs cardiovascular diagnosis).
This is due to an indirect effect on the competing events:
patients with a respiratory diagnosis stay much longer
in ICU without NB than patients with a cardiovascular
diagnosis, or in other words, their daily risk of being dis-
charged or dying without NB is reduced (hazard ratios
of both competing events are lower than 1). This addi-
tional impact on the risk of NB is so strong that respiratory
patients acquire more NB than cardiovascular patients
even though their daily risk of NB is reduced. These
results highlight just some the complexities of exam-
ining risk factors of NI in the presence of competing
risks.
Multilevel risk factors: ICU level
A larger number of beds in an ICU was somewhat indi-
rectly associated with an increased risk of NB (Table 2)
because the number of beds in ICUs were moderately
associated with the competing events. The rate of NB
was higher in university/teaching hospitals compared
with those without teaching, an effect which has also
been found elsewhere [18]. This effect is even more pro-
nounced in the subdistribution model because patients in
non-teaching hospitals are discharged quicker.
Discussion
In this paper, we used two multilevel competing risks
models to evaluate risk factors of NI. To our knowl-
edge, this is the first study to investigate the heterogeneity
across ICUs in risks and rates of NI using a large multicen-
ter cohort accounting for both ICU clustering effects and
competing risks. Further, we showed that it is necessary
to perform a multilevel competing risk analysis to under-
stand fully the direct and indirect effects of risk factors on
the occurrence of NI.
Our findings have the following implications. First, the
large heterogeneity indicates that the impact of unob-
served ICU-specific factors on the risk and rate of NI
is large, even after accounting for important patient-
and observed ICU-level characteristics. Thus, surveillance
networks are encouraged to collect further potential ICU-
level risk factors in addition to patient-level data. This
large heterogeneity might also explain why ICU-based
infection control strategies might work in some ICUs
but not in others. It emphasizes the need for multicen-
ter intervention studies rather than single-center pilot
studies [19,20]. Ignoring heterogeneity in the analysis of
multicenter studies can lead to biased results and mis-
leading conclusions. In our cohort, the risks of NI were
more heterogeneous than rates of NI across ICUs. From
the mathematical point of view, this is not necessarily
the case since different correlations between competing
hazard constellations could potentially result in a very
similar risk of NI.
Second, competing risks play an essential role in the
understanding of NI occurrence and the analysis must
account for this [7]. The distinction between indirect and
direct effects is a key issue for understanding the associa-
tions between risk factors and NI outcomes. For instance,
a cohort study of African children reported no associa-
tion between burns and pediatric hospital-acquired bac-
teremia [21] even though the cumulative risk is about
three times higher, due to competing events [7]. There-
fore, we recommend that the results from both mod-
els (the rate and the risk models) are reported [22] to
make hidden and indirect effects transparent. This is very
important for NI since risk factors for NI are often also
associated with the competing risks for NI as well. This
may result in more pronounced effects in the risk model
(such as APACHE II score, type of diagnosis or trauma) or
effects that are relevant only in the rate model but irrel-
evant in the risk model (e.g., antibiotic treatment before
ICU admission). It could even lead to apparent diamet-
rically opposed results (e.g., both respiratory and central
nervous system vs cardiovascular diagnoses). Third, our
approach has the potential to identify ICUs with unusu-
ally high or low rates. Nevertheless, we emphasize that
extreme caution is needed when using NI rates or risks for
benchmarking or as quality indicators. Besides problems
in reliability, validity [23] and statistical uncertainty, there
are further complications from competing risks as shown
here.
There are some limitations to our study. As in other
large surveillance studies based on volunteer ICUs, data
can be subject to reporting, information or selection bias.
Therefore, it is possible that part of the heterogeneity
might be attributed to over- or under-reporting of NI
rather than to real ICU factors [24]. Information bias
might occur due to unreported NB cases. As suggested by
Hansen et al. [18], surveillance data need to be validated
to counter differences across ICUs. Further, an extrapola-
tion of our findings to other European countries is limited
due to differences in ICU management.
Multilevel analyses in hospital infection epidemiology
are still rare but necessary to evaluate effects of individual-
level and group-level factors [4]. Vellinga et al. have pro-
duced a valuable overview of the principles of multilevel
analysis for antimicrobial resistance studies [5]. We have
extended their methodology to complex survival data for
hospital infections because modeling the timing of events
(infection, death or discharge) is crucial.
Conclusions
We encourage further investigations using our method-
ological approaches, e.g., to evaluate the occurrence of
antimicrobial resistance by exploring antibiotic usage at
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the patient level and ICU level simultaneously. Statis-
tical models and corresponding codes are available in
Additional file 1.
Keymessages
• Discharge from and death in an intensive care unit
are competing risks for nosocomial infection.
• There are factors on the patient as well as on the
ICU level influencing the occurrence of nosocomial
infections.
• Analysis of data from large multicenter studies has
the potential to improve our understanding of how
patient and ICU-level characteristics impact
nosocomial infections.
• A combination of multilevel and competing risk
models are necessary to analyze such complex data.
• We encourage further investigations by using our
methodological approaches to evaluate our findings
of unexplained heterogeneity. The statistical code is
available in Additional file 1.
Additional file
Additional file 1: Appendix: Statistical methods and R code for
multilevel competing risk models.
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